Product details
Catalog number ET1705-95
DiscontinuedPrice for ET1705-95
Size / count 100 µL
This variant is discontinued and cannot be added to your cart.
SATB2 (Special AT-rich sequence-binding protein 2) is a nuclear matrix protein that influences craniofacial formation mechanisms, such as jaw and palate development, and is part of a transcriptional network regulating skeletal development and osteoblast differentiation. Highly expressed in adult and fetal brain, SATB2 contains two CUT DNA-binding domains and one homeobox domain and is closely related to SATB1, a transcriptional repressor. SATB2 is thought to bind to matrix-attachment regions (MARs) and regulate MAR-dependent transcription of various genes, including HoxA2 and ATF4 (CREB-2), involved in skeletal development. Functioning as both a transcriptional activator and repressor, SATB2 can also act as a protein scaffold that can enhance the activity of other DNA-binding proteins. Defects in the gene encoding SATB2 are the cause of cleft palate manifested in conjunction with severe mental retardation.
The catalog number for SATB2 Recombinant Rabbit Monoclonal Antibody [JM52-44] is ET1705-95.
SATB2 Recombinant Rabbit Monoclonal Antibody [JM52-44] is currently made to order / not held in immediate stock. Contact us for lead time.
SATB2 (Special AT-rich sequence-binding protein 2) is a nuclear matrix protein that influences craniofacial formation mechanisms, such as jaw and palate development, and is part of a transcriptional network regulating skeletal development and osteoblast differentiation. Highly expressed in adult and
Shipping temperature is chosen based on the product’s stability needs, ranging from ambient to dry ice, and is indicated on the product page. Any related shipping fee is shown clearly in your quotation.
Molecular weight information, where applicable, is listed on the datasheet under target details, useful for confirming the correct band on western blot.
Lead times depend on the product type: custom polyclonal antibodies typically take 12-14 weeks, monoclonal antibodies 15-17 weeks, made-to-order recombinant proteins 4-8 weeks, and made-to-order recombinant antibodies 6-8 weeks. These are estimates and may shift due to production delays.